[1]Scheltens P, Blennow K, Breteler M M, et al.Alzheimer's disease[J].Lancet, 2016, 388(10043):505-517
[2]Frisoni G B, Boccardi M, Barkhof F, et al.Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers[J].Lancet Neurol, 2017, 16(8):661-676
[3]Castellani R J, Perry G.Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress[J].Arch Med Res, 2012, 43(8):694-698
[4]Lane C A, Hardy J, Schott J M.Alzheimer's disease[J].Eur J Neurol, 2018, 25(1):59-70
[5]Alzheimer' s A.Alzheimer's disease facts and figures[J].Alzheimers Dement, 2016, 12(4):459-509
[6]Villemagne V L, Dore V, Burnham S C, et al.Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions[J].Nat Rev Neurol, 2018, 14(4):225-236
[7]Kalia L V, Lang A E.Parkinson's disease[J].Lancet, 2015, 386(9996):896-912
[8]Goedert M, Spillantini M G, Del Tredici K, et al.years of Lewy pathology[J].Nat Rev Neurol, 2013, 9(1):13-24
[9]Grima J C, Daigle J G, Arbez N, et al.Mutant Huntingtin Disrupts the Nuclear Pore Complex[J].Neuron, 2017, 94(1):93-107
[10]Aguzzi A, Falsig J.Prion propagation,toxicity and degradation[J].Nat Neurosci, 2012, 15(7):936-939
[11]Knowles T P, Vendruscolo M, Dobson C M.The amyloid state and its association with protein misfolding diseases[J].Nat Rev Mol Cell Biol, 2014, 15(6):384-396
[12]Dobson C M.Protein folding and misfolding[J].Nature, 2003, 426(6968):884-890
[13]Chiti F, Dobson C M.Protein misfolding, functional amyloid, and human disease.[J].Annu Rev Biochem, 2006, 75(75):333-366
[14]Guerrero-Munoz M J, Castillo-Carranza D L, Kayed R.Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins[J].Biochem Pharmacol, 2014, 88(4):468-478
[15]Kayed R, Lasagna-Reeves C A.Molecular mechanisms of amyloid oligomers toxicity [J].J Alzheimers Dis, 2013, 33 ( Suppl 1):S67-S78
[16]Kayed R, Head E, Thompson J L, et al.Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis[J].Science, 2003, 300(5618):486-489
[17]Tay T L, Savage J C, Hui C W, et al.Microglia across the lifespan: from origin to function in brain development,plasticity and cognition[J].J Physiol, 2017, 595(6):1929-1945
[18]Salter M W, Beggs S.Sublime microglia: expanding roles for the guardians of the CNS[J].Cell, 2014, 158(1):15-24
[19]Colonna M, Butovsky O.Microglia Function in the Central Nervous System During Health and Neurodegeneration[J].Annu Rev Immunol, 2017, 35(35):441-468
[20]Salter M W, Stevens B.Microglia emerge as central players in brain disease[J].Nat Med, 2017, 23(9):1018-1027
[21]Vilhardt F.Microglia: phagocyte and glia cell[J].Int J Biochem Cell Biol, 2005, 37(1):17-21
[22]Koeglsperger T, Li S, Brenneis C, et al.Impaired glutamate recycling and GluN2B-mediated neuronal calcium overload in mice lacking TGF-beta1 in the CNS[J].Glia, 2013, 61(6):985-1002
[23]Mills C D.M1 and M2 Macrophages: Oracles of Health and Disease[J].Critical Reviews in Immunology, 2012, 32(06):463-488
[24]Salter M W, Stevens B.Microglia emerge as central players in brain disease[J].Nature Medicine, 2017, 23(9):1018-1027
[25]Hansen D V, Hanson J E, Sheng M.Microglia in Alzheimer's disease[J].J Cell Biol, 2018, 217(2):459-472
[26]Fourgeaud L, Traves P G, Tufail Y, et al.TAM receptors regulate multiple features of microglial physiology[J].Nature, 2016, 532(7598):240-244
[27]Schafer D P, Lehrman E K, Stevens B.The "quad-partite" synapse: microglia-synapse interactions in the developing and mature CNS[J].Glia, 2013, 61(1):24-36
[28]Derecki N C, Katzmarski N, Kipnis J, et al.Microglia as a critical player in both developmental and late-life CNS pathologies[J].Acta Neuropathologica, 2014, 128(3):333-345
[29]Wu Y W, Dissing-Olesen L, MacVicar B A, et al.Microglia: Dynamic Mediators of Synapse Development and Plasticity[J].Trends in Immunology, 2015, 36(10):605-613
[30]Hanisch U K.Microglia as a source and target of cytokines[J].Glia, 2002, 40(2):140-155
[31]Cameron B, Landreth G E.Inflammation,microglia,and Alzheimer's disease[J].Neurobiol Dis, 2010, 37(3):503-509
[32]Liddelow S A, Guttenplan K A, Larke L E C, et al.Neurotoxic reactive astrocytes are induced by activated microglia[J].Nature, 2017, 541(7638):481-487
[33]Deierborg T, Roybon L, Inacio A R, et al.Brain injury activates microglia that induce neural stem cell proliferation ex vivo and promote differentiation of neurosphere-derived cells into neurons and oligodendrocytes[J].Neuroscience, 2010, 171(4):1386-1396
[34]Perry V H, Holmes C.Microglial priming in neurodegenerative disease[J].Nat Rev Neurol, 2014, 10(4):217-224
[35]Blennow K, de Leon M J, Zetterberg H.Alzheimer's disease[J].Lancet, 2006, 368(9533):387-403
[36]Fonseca M I, Chu S H, Hernandez M X, et al.Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain[J].J Neuroinflammation, 2017, 14(1):48-62
[37]Selkoe D J, Hardy J.The amyloid hypothesis of Alzheimer's disease at 25years[J].Embo Molecular Medicine, 2016, 8(6):595-608
[38]Abbott A, Dolgin E.Failed Alzheimer's trial does not kill leading theory of disease[J].Nature, 2016, 540(7631):15-16
[39]Polanco J C, Li C, Bodea L G, et al.Amyloid-beta and tau complexity - towards improved biomarkers and targeted therapies[J].Nat Rev Neurol, 2018, 14(1):22-39
[40]Forloni G, Artuso V, La Vitola P, et al.Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases[J].Mov Disord, 2016, 31(6):771-781
[41]Hong S, Beja-Glasser V F, Nfonoyim B M, et al.Complement and microglia mediate early synapse loss in Alzheimer mouse models[J].Science, 2016, 352(6286):712-716
[42]Koenigsknecht-Talboo J, Landreth G E.Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines[J].J Neurosci, 2005, 25(36):8240-8249
[43]von Bernhardi R, Ramirez G, Toro R, et al.Pro-inflammatory conditions promote neuronal damage mediated by Amyloid Precursor Protein and decrease its phagocytosis and degradation by microglial cells in culture[J].Neurobiol Dis, 2007, 26(1):153-164
[44]Weiner H L, Frenkel D.Immunology and immunotherapy of Alzheimer's disease[J].Nat Rev Immunol, 2006, 6(5):404-416
[45]Yeh F L, Hansen D V, Sheng M.TREM2,Microglia,and Neurodegenerative Diseases[J].Trends Mol Med, 2017, 23(6):512-533
[46]Terwel D, Steffensen K R, Verghese P B, et al.Critical role of astroglial apolipoprotein E and liver X receptor-alpha for microglial Abeta phagocytosis[J].J Neurosci, 2011, 31(19):7049-7059
[47]Jaworski T, Lechat B, Demedts D, et al.Dendritic degeneration,neurovascular defects,and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration[J].Am J Pathol, 2011, 179(4):2001-2015
[48]Britschgi M, Takeda-Uchimura Y, Rockenstein E, et al.Deficiency of terminal complement pathway inhibitor promotes neuronal tau pathology and degeneration in mice [J].J Neuroinflammation, 2012, 9(9):220-225
[49]Fonseca M I, Ager R R, Chu S H, et al.Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease[J].J Immunol, 2009, 183(2):1375-83
[50]Asai H, Ikezu S, Tsunoda S, et al.Depletion of microglia and inhibition of exosome synthesis halt tau propagation[J].Nat Neurosci, 2015, 18(11):1584-1593
[51]Maphis N, Xu G, Kokiko-Cochran O N, et al.Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain[J].Brain, 2015, 138(Pt 6):1738-1755
[52]Cho S H, Sun B, Zhou Y, et al.CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease[J].J Biol Chem, 2011, 286(37):32713-32722
[53]Bhaskar K, Konerth M, Kokiko-Cochran O N, et al.Regulation of tau pathology by the microglial fractalkine receptor[J].Neuron, 2010, 68(1):19-31
[54]Shi Y, Yamada K, Liddelow S A, et al.ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy[J].Nature, 2017, 549(7673):523-527
[55]Harris K P, Littleton J T.Transmission,Development,and Plasticity of Synapses[J].Genetics, 2015, 201(2):345-375
[56]Lin Y C, Koleske A J.Mechanisms of Synapse and Dendrite Maintenance and Their Disruption in Psychiatric and Neurodegenerative Disorders[J].Annual Review of Neuroscience, 2010, 33 (33):349-378
[57]Campagne M V, Wiesmann C, Brown E J.Macrophage complement receptors and pathogen clearance[J].Cellular Microbiology, 2007, 9(9):2095-2102
[58]Stephan A H, Barres B A, Stevens B.The Complement System: An Unexpected Role in Synaptic Pruning During Development and Disease[J].Annual Review of Neuroscience, 2012, 35(35):369-389
[59]Presumey J, Bialas A R, Carroll M C.Complement System in Neural Synapse Elimination in Development and Disease[J].Advances in Immunology, 2017, 135(135):53-79
[60]Courchesne E, Mouton P R, Calhoun M E, et al.Neuron Number and Size in Prefrontal Cortex of Children With Autism[J].Jama-Journal of the American Medical Association, 2011, 306(18):2001-2010
[61]Willison H J, Jacobs B C, van Doorn P A.Guillain-Barre syndrome[J].Lancet, 2016, 388(10045):717-727
[62]Zamanian J L, Xu L J, Foo L C, et al.Genomic Analysis of Reactive Astrogliosis[J].Journal of Neuroscience, 2012, 32(18):6391-6410
[63]Spangenberg E E, Lee R J, Najafi A R, et al.Eliminating microglia in Alzheimer' s mice prevents neuronal loss without modulating amyloid-beta pathology[J].Brain, 2016, 139(139):1265-1281
[64]Olmos-Alonso A, Schetters S T, Sri S, et al.Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology[J].Brain, 2016, 139(Pt 3):891-907
[65]Paolicelli R C, Jawaid A, Henstridge C M, et al.TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss[J].Neuron, 2017, 95(2):297-308
[66]Rabinovich-Nikitin I, Ezra A, Barbiro B, et al.Chronic administration of AMD3100 increases survival and alleviates pathology in SOD1(G93A) mice model of ALS[J].J Neuroinflammation, 2016, 13(1):123-133
[67]Carty M, Bowie A G.Evaluating the role of Toll-like receptors in diseases of the central nervous system[J].Biochem Pharmacol, 2011, 81(7):825-837
